The main objective of this project is to gain insight into the progression of gray matter (GM) atrophy in multiple sclerosis (MS) patients through advanced magnetic resonance imaging (MRI) and newly developed image analysis methods. Gray matter tissue damage is a major component of overall MS pathology in the brain. However, relatively little is known about GM pathology in MS patients because the majority of focal GM lesions cannot be detected with MRI. GM atrophy, on the other hand, can be measured reliably with accurate image analysis methods and can be used to estimate the total extent of destructive GM pathology. GM atrophy is likely due to a combination of severe tissue damage in the GM itself and neurodegeneration secondary to damage in the white matter (WM). The relative contributions of each and how these change over the course of disease are unknown. In this project, a longitudinal MRI study of 70 MS patients and 17 healthy controls will be extended (from 9 to 14 years) and new image analysis methods, based explicitly on findings from post-mortem MRI/pathology correlation studies, will be developed and applied in order to (1) Determine the relationship between specific types of pathologically-validated, MRI-defined WM lesion subtypes and GM atrophy;(2) Assess the degree to which specific types of pathologically-validated, MRI-defined damage in normal-appearing brain tissue regions are related to GM atrophy;and (3) Determine the pathologic and clinical significance of GM atrophy in post-mortem and long-term follow-up studies. The first two aims seek to identify new in vivo MRI markers that are strongly correlated to GM tissue damage based on the pathologic correlates of MRI characterstics in MS brains post-mortem. Application of these new markers in the longitudinally-followed patient group will help to elucidate the mechanisms and time course of GM atrophy progression.
The third aim will help to validate GM atrophy measurements. In the first part of Aim 3, post-mortem MRI-guided pathology will be used to determine how cortical thinning relates to focal pathology in GM. The second part of Aim 3 will use data from the longitudinal study to determine how overall GM atrophy and regional changes in cortical thickness relate to the progression of disability and cognitive deficits in patients with MS. Through discovery and validation of new MRI markers of MS pathology in gray matter, this study will lead to a better understanding of MS and improved tools for patient monitoring and evaluation of potential neuroprotective therapies.
Multiple sclerosis affects the gray matter as much as the white matter in the brain. MRI is commonly used to monitor MS patients, but it is insensitive to most gray matter tissue damage. This study will develop and validate new MRI markers of GM pathology in order to provide a more complete picture of the disease. MRI-based measurements of GM tissue damage will lead to a better understanding of MS and improved tools for monitoring MS patients and for evaluating potential neuroprotective therapies.
|Takeshita, Yukio; Obermeier, Birgit; Cotleur, Anne et al. (2014) An in vitro blood-brain barrier model combining shear stress and endothelial cell/astrocyte co-culture. J Neurosci Methods 232:165-72|
|Dutta, Ranjan; Trapp, Bruce D (2014) Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 27:271-8|
|Criste, Gerson; Trapp, Bruce; Dutta, Ranjan (2014) Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol 122:101-13|
|Tutuncu, Melih; Tang, Junger; Zeid, Nuhad Abou et al. (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19:188-98|
|Chen, Jacqueline Tien-Hsiang; Easley, Kathryn; Schneider, Colleen et al. (2013) Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology 80:246-52|
|Rudick, Richard A; Fisher, Elizabeth (2013) Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes. Mult Scler 19:1003-4|
|Erbayat Altay, Edru; Fisher, Elizabeth; Jones, Stephen E et al. (2013) Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol 70:338-44|
|Dutta, Ranjan; Trapp, Bruce D (2012) Gene expression profiling in multiple sclerosis brain. Neurobiol Dis 45:108-14|
|Rudick, Richard A; Rani, M R Sandhya; Xu, Yaomin et al. (2011) Excessive biologic response to IFNýý is associated with poor treatment response in patients with multiple sclerosis. PLoS One 6:e19262|
|Dutta, Ranjan; Trapp, Bruce D (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93:1-12|
Showing the most recent 10 out of 21 publications